Obesity is a major feature in women with polycystic ovary syndrome (PCOS), and evidence suggests that obesity contributes to the pathogenesis of PCOS by aggravating the intrinsic insulin resistance of these women. Hyperinsulinemia appears to increase circulating androgens in PCOS by stimulating ovarian androgen production and suppressing serum SHBG, and also appears to play a pathogenic role in the anovulation of the disorder. The use of insulin sensitizing drugs has been shown to decrease serum insulin in both obese and nonobese women with PCOS, and to simultaneously reduce circulating ovarian androgens and to improve ovulation. International Journal of Obesity (2000) 24, Suppl 2, S71±S73
Introduction
Obesity is a prominent feature of the polycystic ovary syndrome (PCOS), a disorder characterized by chronic anovulation and hyperandrogenism. PCOS affects approximately 6% of women of childbearing age, and between 50 ± 80% of women with PCOS are obese. Moreover, many women with PCOS have a history of weight gain immediately preceding the onset of oligomenorrhea, suggesting that obesity plays a pathogenic role in the disorder.
Within the past decade, it has become apparent that hyperinsulinemic insulin resistance is a prominent feature of many women with PCOS, even in nonobese women with the disorder, and that hyperinsulinemia plays a pivotal role in the disorder by stimulating ovarian androgen production and impeding ovation. Hyperinsulinemic insulin resistance is a feature common to both obesity and PCOS and, as will be discussed subsequently, it seems likely that obesity contributes to the development of PCOS in some women by exacerbating a preexisting (likely inherited form of) insulin resistance.
Insulin resistance: an integral feature of PCOS
In multiple studies, both obese and nonobese women with PCOS have been shown to be insulin-resistant and hyperinsulinemic compared with age-and weightmatched normal women. 1 ± 4 This holds true across multiple ethnic groups and cultures, 5 suggesting that insulin resistance and hyperinsulinemia represent almost universal features of PCOS.
Evidence that hyperinsulinemia stimulates ovarian androgen production
The strongest evidence indicating that hyperinsulinemia increases circulating androgens in women with PCOS comes from studies using the drug diazoxide 6 ± 8 which directly inhibits pancreatic insulin release. When we administered diazoxide to ®ve obese women with PCOS for 10 days, their fasting and glucose-stimulated serum insulin concentrations decreased and serum glucose increased. 6 Importantly, during suppression of insulin release by diazoxide, serum total testosterone concentrations decreased and serum sex hormone-binding globulin (SHBG) concentrations increased in all ®ve women. As a result of these events, serum-free (ie non-SHBG-bound) testosterone concentrations decreased by 28% (P`0.01) in the women.
To exclude the possibility that the decline in circulating free testosterone was due to diazoxide itself, we then studied ®ve healthy women of normal weight in an identical fashion. 7 In contrast to the obese women with PCOS, diazoxide treatment altered neither serum testosterone nor SHBG in this group of lean women with normal levels of circulating insulin, indicating that diazoxide does not in¯uence ovarian steroidogenic function independently of its action to inhibit insulin release.
Insulin also directly decreases serum SHBG concentrations in PCOS, independently of any action on sex steroids. This was demonstrated in women with PCOS by ®rst suppressing ovarian sex steroid production for two months with a GnRH agonist (leuprolide) and then inhibiting insulin release with diazoxide. 8 Serum SHBG did not change when leuprolide alone was administered, despite substantial decreases in serum androgens and estrogens, but increased signi®-cantly during simultaneous diazoxide administration. These ®ndings indicate that insulin increases serumfree testosterone in PCOS via two separate mech-anisms: (1) by increasing circulating ovarian androgens, and (2) by suppressing serum SHBG.
An important conclusion that can be drawn from the above studies is that hyperinsulinemia is the culprit that stimulates ovarian androgen production and suppresses serum SHBG in PCOS. That is, it is not insulin resistance at the ovarian or hepatic level that is pathogenic Ð rather, it is the elevation in circulating insulin. This is evident because diazoxide speci®cally inhibits insulin release, and is not known to in¯uence insulin sensitivity in human beings.
Subsequent studies using the insulin sensitizing agents metformin 9 ± 16 and troglitazone 17,18 have con®rmed the ®ndings of the diazoxide studies. Administration of either metformin or troglitazone was associated with a decrease in serum insulin (because of improved peripheral insulin sensitivity), and with concurrent decreases in serum-free testosterone and increases in serum SHBG.
Insulin appears to increase circulating androgens by stimulating ovarian androgen production, as evidenced by studies that used the GnRH agonist (leuprolide) stimulation test to assess ovarian cytochrome P450c17a activity before and after metformin administration.
12,15 Ovarian P450c17a activity decreased markedly in obese 15 and lean 12 women with PCOS after reduction of serum insulin with metformin. It is unclear whether hyperinsulinemia stimulates ovarian androgen production directly or indirectly by affecting gonadotropins, or by a combination of these events. It is also unknown if hyperinsulinemia affects the metabolic clearance rate of ovarian androgens.
Evidence that hyperinsulinemia impedes ovulation
Theoretically, hyperinsulinemia could adversely affect folliculogenesis and the orderly¯ow to ovulation by several mechanisms, eg by increasing intraovarian androgens, by perturbing gonadotropin release, or by directly altering follicular development. Insulin could accomplish the latter through its actions as a mitogenic factor, or by stimulating local tissue production of other growth factors or potentiating their effects.
It was reported that administration of metformin 10,12,13,15,16 and troglitazone 17,18 was associated with improved menstrual cyclicity in woman with PCOS. A study that directly and critically assessed the effects of insulin reduction on ovulation in PCOS was recently reported.
11 This study was conducted in the United States, Italy and Venezuela, and used metformin to enhance peripheral insulin sensitivity and reduce serum insulin. Treatment with metformin was shown to increased the spontaneous ovulation rate in women with PCOS by greater than 8-fold over a ®ve week treatment period, compared with women who received placebo. Those women who did not ovulate spontaneously were then administered 50 mg of clomiphene daily for 5 days while continuing metformin or placebo administration. The women who received metformin demonstrated a greater than 10-fold increase in clomiphene-induced ovulation, compared with the women who received placebo. Collectively 89% of the women who received metformin ovulated either spontaneously or in response to clomiphene, compared with only 12% of the women who received placebo. These results strongly suggested that hyperinsulinemia impedes ovulation in women with PCOS, and that insulin-sensitizing drugs can be used as primary or adjuvant therapy for the anovulation of PCOS.
Finally, it has been long recognized that obesity is associated with reproductive abnormalities, and that weight loss in obese women with PCOS is associated with improved menstrual cyclicity and fertility. The results of the metformin studies suggest that the improvement with weight loss is at least in part due to the enhanced insulin sensitivity and decreased circulating insulin that accompanies weight loss. 
